GT200700077A - Compuestos de 4-metilpiridopirimidinona - Google Patents

Compuestos de 4-metilpiridopirimidinona

Info

Publication number
GT200700077A
GT200700077A GT200700077A GT200700077A GT200700077A GT 200700077 A GT200700077 A GT 200700077A GT 200700077 A GT200700077 A GT 200700077A GT 200700077 A GT200700077 A GT 200700077A GT 200700077 A GT200700077 A GT 200700077A
Authority
GT
Guatemala
Prior art keywords
compounds
methylpiridopirimidinone
phosfoinositized
quinase
modulators
Prior art date
Application number
GT200700077A
Other languages
English (en)
Inventor
Hengmiao Cheng
Dilip Bhumralkar
Klaus Ruprecht Dress
Jacqui Elizabeth Hoffman
Mary Catherine Johnson
Robert Steven Kania
Phuong Thi Quy Le
Mitchell David Nambu
Mason Alan Pairish
Michael Bruno Plewe
Khanh Tuan Tran
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of GT200700077A publication Critical patent/GT200700077A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pyridine Compounds (AREA)

Abstract

LA PRESENTE INVENCIÓN SE REFIERE A COMPUESTOS DE FÓRMULA GENERAL I EN LA QUE R1,R2,R3,R4,Z, SON GRUPOS FUNCIONALES DESCRITOS EN EL EXPEDIENTE. ESTOS COMPUESTOS SON MODULADORES O INHIBIDORES DE LA ENZIMA FOSFOINOSITIDO 3-QUINASA ALFA POR LO QUE SON DE UTILIDAD EN CUADROS O ESTADOS PATOLÓGICOS ASOCIADOS A CRECIMIENTO ANORMAL DE CÉLULAS TALES COMO EL CÁNCER.
GT200700077A 2006-09-15 2007-09-13 Compuestos de 4-metilpiridopirimidinona GT200700077A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US84506506P 2006-09-15 2006-09-15
US94785207P 2007-07-03 2007-07-03
US95262807P 2007-07-30 2007-07-30

Publications (1)

Publication Number Publication Date
GT200700077A true GT200700077A (es) 2009-08-03

Family

ID=38859750

Family Applications (1)

Application Number Title Priority Date Filing Date
GT200700077A GT200700077A (es) 2006-09-15 2007-09-13 Compuestos de 4-metilpiridopirimidinona

Country Status (42)

Country Link
US (3) US7696213B2 (es)
EP (1) EP2074122B9 (es)
JP (1) JP4718637B2 (es)
KR (1) KR101099926B1 (es)
CN (1) CN101573358B (es)
AP (1) AP2710A (es)
AR (1) AR062785A1 (es)
AT (1) ATE514695T1 (es)
AU (1) AU2007297212B8 (es)
BR (1) BRPI0716749B8 (es)
CA (1) CA2663401C (es)
CL (1) CL2007002682A1 (es)
CR (1) CR10662A (es)
CU (1) CU23783B7 (es)
CY (1) CY1111911T1 (es)
DK (1) DK2074122T5 (es)
DO (1) DOP2009000039A (es)
EA (1) EA016388B1 (es)
ES (1) ES2366489T3 (es)
GE (1) GEP20115306B (es)
GT (1) GT200700077A (es)
HK (1) HK1138589A1 (es)
HN (1) HN2007000267A (es)
HR (1) HRP20110621T2 (es)
IL (1) IL197243A (es)
MA (1) MA30709B1 (es)
ME (1) MEP8009A (es)
MX (1) MX2009002927A (es)
MY (1) MY146420A (es)
NI (1) NI200900032A (es)
NO (1) NO342357B1 (es)
NZ (1) NZ575167A (es)
PE (1) PE20080670A1 (es)
PL (1) PL2074122T3 (es)
PT (1) PT2074122E (es)
RS (2) RS20090104A (es)
SI (1) SI2074122T1 (es)
TN (1) TN2009000085A1 (es)
TW (1) TWI334353B (es)
UY (1) UY30588A1 (es)
WO (1) WO2008032162A1 (es)
ZA (1) ZA200901477B (es)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101573358B (zh) 2006-09-15 2012-05-30 辉瑞产品公司 吡啶并(2,3-d)嘧啶酮化合物及其作为pi3抑制剂的用途
MX2009010930A (es) * 2007-04-10 2010-01-20 Exelixis Inc Metodos para tratar cancer usando inhibidores de piridopirimidinona de pi3k alfa.
EP2142544B8 (en) * 2007-04-11 2013-07-03 Exelixis, Inc. Pyrido [2, 3-d]pyrimidin-7-one compounds as inhibitors of pi3k-alpha for the treatment of cancer
US20110105521A1 (en) * 2008-07-11 2011-05-05 Novartis Ag Combination of (a) a phosphoinositide 3-kinase inhibitor and (b) a modulator of ras/raf/mek pathway
US8715638B2 (en) 2008-08-20 2014-05-06 Merck Sharp & Dohme Corp. Ethenyl-substituted pyridine and pyrimidine derivatives and their use in treating viral infections
CA2734488A1 (en) 2008-08-20 2010-02-25 Southern Research Institute Azo-substituted pyridine and pyrimidine derivatives and their use in treating viral infections
WO2010022125A1 (en) 2008-08-20 2010-02-25 Schering Corporation Ethynyl-substituted pyridine and pyrimidine derivatives and their use in treating viral infections
WO2010022121A1 (en) 2008-08-20 2010-02-25 Schering Corporation Substituted pyridine and pyrimidine derivatives and their use in treating viral infections
TW201018685A (en) * 2008-09-30 2010-05-16 Exelixis Inc Pyridopyrimidinone inhibitors of PI3Kα and mTOR
US9526648B2 (en) 2010-06-13 2016-12-27 Synerz Medical, Inc. Intragastric device for treating obesity
US8628554B2 (en) 2010-06-13 2014-01-14 Virender K. Sharma Intragastric device for treating obesity
US10420665B2 (en) 2010-06-13 2019-09-24 W. L. Gore & Associates, Inc. Intragastric device for treating obesity
US10010439B2 (en) 2010-06-13 2018-07-03 Synerz Medical, Inc. Intragastric device for treating obesity
UA109688C2 (xx) 2010-12-16 2015-09-25 Трициклічні інгібітори pі3k та їх застосування
US8664230B2 (en) * 2011-03-17 2014-03-04 The Asan Foundation Pyridopyrimidine derivatives and use thereof
TW201306842A (zh) * 2011-06-15 2013-02-16 Exelixis Inc 使用ｐｉ３ｋ／ｍｔｏｒ吡啶並嘧啶酮抑制劑及苯達莫司汀及／或利妥昔單抗治療惡性血液疾病之組合療法
RU2607944C2 (ru) 2011-08-31 2017-01-11 Новартис Аг Синергические композиции ингибиторов pi3k и мек
CN104829609B (zh) * 2014-02-11 2016-08-03 北大方正集团有限公司 取代的吡啶并嘧啶化合物及其制备方法和应用
CN105294682B (zh) 2014-07-26 2017-07-07 广东东阳光药业有限公司 Cdk类小分子抑制剂的化合物及其用途
CN105330699B (zh) * 2014-08-13 2018-12-04 山东汇睿迪生物技术有限公司 一种含磷吡啶并[2,3-d]嘧啶-7-酮类化合物或其药学上可接受的盐、药物组合物及其应用
EP3549583A1 (en) 2014-10-10 2019-10-09 Pfizer Inc Synergistic auristatin combinations
KR102068423B1 (ko) 2015-06-04 2020-01-20 화이자 인코포레이티드 팔보시클립의 고체 투여 형태
US10779980B2 (en) 2016-04-27 2020-09-22 Synerz Medical, Inc. Intragastric device for treating obesity
CN109563088B (zh) 2016-07-06 2022-10-11 密歇根大学董事会 MEK/PI3K和mTOR/MEK/PI3K的多功能抑制剂和治疗用途
MX2019001849A (es) 2016-08-15 2019-05-09 Pfizer Inhibidores de cdk2/4/6 de piridopirimidinona.
EP3554558A4 (en) * 2016-12-14 2020-10-28 Tarveda Therapeutics, Inc. HSP90 TARGETING CONJUGATES AND FORMULATIONS OF THE LATEST
US10596165B2 (en) 2018-02-12 2020-03-24 resTORbio, Inc. Combination therapies
CA3103282A1 (en) 2018-06-15 2019-12-19 Navitor Pharmaceuticals, Inc. Rapamycin analogs and uses thereof
CA3124574A1 (en) * 2018-12-28 2020-07-02 Spv Therapeutics Inc. Cyclin-dependent kinase inhibitors
US20220220103A1 (en) * 2018-12-28 2022-07-14 Spv Therapeutics Inc. Cyclin-dependent kinase inhibitors
US11583538B2 (en) 2019-04-08 2023-02-21 Venenum Biodesign, LLC Substituted pyrrolo[1,2-a]pyrazines and pyrrolo[1,2-a][1,4]diazepines as TREX1 inhibitors
JP2023506410A (ja) 2019-12-05 2023-02-16 アナクリア セラピューティクス， インコーポレイテッド ラパマイシン類似体及びその使用
WO2021139775A1 (zh) * 2020-01-10 2021-07-15 江苏先声药业有限公司 吡啶酮化合物及应用
WO2022075974A1 (en) * 2020-10-06 2022-04-14 Venenum Biodesign, LLC Cyclic trex1 inhibitors
US11912668B2 (en) 2020-11-18 2024-02-27 Deciphera Pharmaceuticals, Llc GCN2 and perk kinase inhibitors and methods of use thereof
WO2023092104A1 (en) * 2021-11-18 2023-05-25 Onconova Therapeutics, Inc. Methods and compositions for treating cancer

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5264437A (en) * 1992-03-20 1993-11-23 Syntex (U.S.A.) Inc. Optionally substituted pyrido[2,3-d]pyridine-2,4(1H,3H)-diones and pyrido[2,]pyrimidine-2(1H,3H)-ones
GEP20012444B (en) 1994-11-14 2001-05-25 Warner Lambert Company Us 6-Aryl Pyrido[2,3-d]Pyrimidines and Naphthyridines, Pharmaceutical Composition on Their Basis and Application for Inhibiting Cellular Proliferation
CN1177960A (zh) * 1995-03-10 1998-04-01 圣诺菲药品有限公司 6－取代的吡唑并[3,4－d]嘧啶－4－酮及其组合物和使用方法
IL117923A (en) 1995-05-03 2000-06-01 Warner Lambert Co Anti-cancer pharmaceutical compositions containing polysubstituted pyrido¬2,3-d¾pyrimidine derivatives and certain such novel compounds
US5925761A (en) 1997-02-04 1999-07-20 Sepracor Inc. Synthesis of terfenadine and derivatives
US6498163B1 (en) 1997-02-05 2002-12-24 Warner-Lambert Company Pyrido[2,3-D]pyrimidines and 4-aminopyrimidines as inhibitors of cellular proliferation
JP2001509805A (ja) 1997-02-05 2001-07-24 ワーナー−ランバート・コンパニー 細胞増殖阻害剤としてのピリド〔２，３−ｄ〕ピリミジンおよび４−アミノピリミジン
GB9904932D0 (en) 1999-03-04 1999-04-28 Glaxo Group Ltd Composition and method for preventing/reducing the severity of side effects of chemotherapy and/or radiation therapy
IL150742A0 (en) 2000-01-27 2003-02-12 Warner Lambert Co Pyridopyrimidinone derivatives for the treatment of neurodegenerative disease
NZ520962A (en) 2000-03-06 2003-09-26 Warner Lambert Co 5-alkylpyrido[2,3-d]pyrimidines cyclin-dependent tyrosine kinase inhibitors
EP1277738B1 (en) 2000-04-27 2011-03-30 Astellas Pharma Inc. Condensed heteroaryl derivatives
WO2002068419A1 (fr) 2001-02-26 2002-09-06 Tanabe Seiyaku Co., Ltd. Derive de pyridopyrimidine ou naphthyridine
US7019002B2 (en) * 2001-12-11 2006-03-28 Pharmacia & Upjohn, S.P.A. Pyridopyrimidinones derivatives as telomerase inhibitors
KR20060111716A (ko) 2002-01-22 2006-10-27 워너-램버트 캄파니 엘엘씨 2-(피리딘-2-일아미노)-피리도[2,3-ｄ]피리미딘-7-온
JP2003321472A (ja) 2002-02-26 2003-11-11 Takeda Chem Ind Ltd Ｇｒｋ阻害剤
WO2003088972A1 (en) 2002-04-19 2003-10-30 Smithkline Beecham Corporation Novel compounds
RU2004135392A (ru) 2002-05-06 2005-06-27 Дженелэбс Текнолоджиз, Инк. (Us) Производные нуклеозидов для лечения инфекции, вызываемой вирусом гепатита с
JP2004083587A (ja) 2002-08-06 2004-03-18 Tanabe Seiyaku Co Ltd 医薬組成物
US7098332B2 (en) * 2002-12-20 2006-08-29 Hoffmann-La Roche Inc. 5,8-Dihydro-6H-pyrido[2,3-d]pyrimidin-7-ones
JP2004203751A (ja) 2002-12-24 2004-07-22 Pfizer Inc 置換６，６−ヘテロ二環式誘導体
US20050009849A1 (en) 2003-01-03 2005-01-13 Veach Darren R. Pyridopyrimidine kinase inhibitors
WO2004089930A1 (en) 2003-04-02 2004-10-21 Imclone Systems Incorporated 4-fluoroquinolone derivatives and their use as kinase inhibitors
EP1624900A4 (en) 2003-05-20 2007-05-02 Univ California METHOD OF BINDING AGENTS AT BETA AMYLOID PLAQUE
RU2317296C2 (ru) 2003-07-11 2008-02-20 Уорнер-Ламберт Компани Ллс Изетионатная соль селективного ингибитора cdk4
NZ544697A (en) 2003-07-22 2009-03-31 Janssen Pharmaceutica Nv Quinolinone derivatives as inhibitors of c-fms kinase
US7160888B2 (en) * 2003-08-22 2007-01-09 Warner Lambert Company Llc [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia
US7968557B2 (en) 2004-02-14 2011-06-28 Novartis Ag Substituted pyrrolo[2,3-2]pyrimidines as protein kinase inhibitors
BRPI0507852A (pt) 2004-02-18 2007-07-10 Warner Lambert Co 2-(piridin-3-ilamino)-pirido[2,3-d]pirimidin-7-onas
JP2007530654A (ja) 2004-03-30 2007-11-01 ファイザー・プロダクツ・インク シグナル伝達阻害剤の組合せ
WO2005105097A2 (en) 2004-04-28 2005-11-10 Gpc Biotech Ag Pyridopyrimidines for treating inflammatory and other diseases
ES2292130T3 (es) * 2004-05-04 2008-03-01 Warner-Lambert Company Llc Pirido(2,3-d)pirimidin-7-onas pirrolil-sustituidas y derivados de las mismas como agentes terapeuticos.
WO2005117980A1 (en) 2004-06-04 2005-12-15 Pfizer Products Inc. Method for treating abnormal cell growth
JP2008510770A (ja) 2004-08-26 2008-04-10 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｐｌｋ阻害剤としての新規プテリジノン
CA2585091C (en) 2004-11-03 2016-07-19 University Of Kansas Novobiocin analogues as anticancer agents
JP5111113B2 (ja) 2004-12-13 2012-12-26 サネシス ファーマシューティカルズ， インコーポレイテッド Ｒａｆキナーゼ阻害剤として有用なピリドピリミジノン、ジヒドロピリミドピリミジノンおよびプテリジノン
US20060142312A1 (en) 2004-12-23 2006-06-29 Pfizer Inc C6-aryl and heteroaryl substituted pyrido[2,3-D] pyrimidin-7-ones
CA2624965A1 (en) * 2005-10-07 2007-04-19 Exelixis, Inc. Pyridopyrimidinone inhibitors of pi3k.alpha.
EP2322523B1 (en) * 2005-10-07 2019-01-02 Exelixis, Inc. Process for the preparation of Pyridopyrimidinone Inhibitors of PI3Kalpha
EP1872922A1 (en) * 2006-06-27 2008-01-02 Nederlandse Organisatie voor Toegepast-Natuuurwetenschappelijk Onderzoek TNO Method and apparatus for manufacturing a polymeric article
CN101528231A (zh) 2006-08-16 2009-09-09 埃克塞利希斯股份有限公司 在癌症的治疗中使用pi3k和mek调控剂
CN101573358B (zh) 2006-09-15 2012-05-30 辉瑞产品公司 吡啶并(2,3-d)嘧啶酮化合物及其作为pi3抑制剂的用途
GEP20135925B (en) * 2007-03-14 2013-10-10 Exelixis Patent Co Llc Inhibitors of hedgehog pathway
EP2142544B8 (en) 2007-04-11 2013-07-03 Exelixis, Inc. Pyrido [2, 3-d]pyrimidin-7-one compounds as inhibitors of pi3k-alpha for the treatment of cancer
TW201018685A (en) 2008-09-30 2010-05-16 Exelixis Inc Pyridopyrimidinone inhibitors of PI3Kα and mTOR
CN102970868A (zh) * 2010-04-16 2013-03-13 柯瑞斯公司 具有k-ras突变的癌症的治疗

Also Published As

Publication number Publication date
HRP20110621T2 (hr) 2013-12-06
PL2074122T3 (pl) 2011-10-31
CA2663401C (en) 2011-07-12
MEP8009A (en) 2011-12-20
TW200820972A (en) 2008-05-16
DK2074122T5 (da) 2014-03-17
WO2008032162A8 (en) 2009-03-26
DOP2009000039A (es) 2015-12-15
BRPI0716749A2 (pt) 2014-02-18
CA2663401A1 (en) 2008-03-20
ES2366489T9 (es) 2013-12-27
US8633204B2 (en) 2014-01-21
BRPI0716749B1 (pt) 2020-10-06
US20120309775A1 (en) 2012-12-06
MX2009002927A (es) 2009-03-31
UY30588A1 (es) 2008-05-02
US20080090801A1 (en) 2008-04-17
EA016388B1 (ru) 2012-04-30
CN101573358B (zh) 2012-05-30
PE20080670A1 (es) 2008-06-14
NO20091141L (no) 2009-03-31
PT2074122E (pt) 2011-08-24
MY146420A (en) 2012-08-15
WO2008032162A1 (en) 2008-03-20
NO342357B1 (no) 2018-05-14
EP2074122B1 (en) 2011-06-29
IL197243A0 (en) 2009-12-24
BRPI0716749B8 (pt) 2021-05-25
MA30709B1 (fr) 2009-09-01
EP2074122A1 (en) 2009-07-01
AP2009004790A0 (en) 2009-04-30
IL197243A (en) 2013-07-31
SI2074122T1 (sl) 2011-10-28
GEP20115306B (es) 2011-10-10
CU20090040A7 (es) 2011-07-11
DK2074122T3 (da) 2011-08-15
NZ575167A (en) 2010-10-29
EA200970207A1 (ru) 2009-08-28
JP4718637B2 (ja) 2011-07-06
HN2007000267A (es) 2011-02-25
TN2009000085A1 (fr) 2010-08-19
NI200900032A (es) 2010-05-14
AR062785A1 (es) 2008-12-03
US7696213B2 (en) 2010-04-13
AP2710A (en) 2013-07-30
RS51927B (en) 2012-02-29
KR101099926B1 (ko) 2011-12-28
JP2010503653A (ja) 2010-02-04
AU2007297212B2 (en) 2011-04-14
CL2007002682A1 (es) 2008-04-04
CU23783B7 (es) 2012-02-15
CR10662A (es) 2009-04-17
CN101573358A (zh) 2009-11-04
AU2007297212B8 (en) 2011-04-28
HK1138589A1 (en) 2010-08-27
US8273755B2 (en) 2012-09-25
ZA200901477B (en) 2010-07-28
CY1111911T1 (el) 2015-11-04
EP2074122B9 (en) 2013-09-11
KR20090040389A (ko) 2009-04-23
ES2366489T3 (es) 2011-10-20
AU2007297212A1 (en) 2008-03-20
TWI334353B (en) 2010-12-11
ATE514695T1 (de) 2011-07-15
US20100137279A1 (en) 2010-06-03
HRP20110621T1 (en) 2011-09-30
RS20090104A (en) 2010-06-30

Similar Documents

Publication Publication Date Title
GT200700077A (es) Compuestos de 4-metilpiridopirimidinona
UY39128A (es) Composiciones y métodos para modular la senda de señalización de wnt
GT200700039A (es) Derivados de triazolopirazina
GT200500226A (es) Compuestos de aminoheteroarilo sustituidos con pirazol como inhibidores de proteina quinasa
GT200600306A (es) Inhibidores de glutamato agrecanasa
GT200600174A (es) Pirrolopiridinas sustituidas, composiciones que las contienen, proceso de fabricacion y utilizacion
GT200800170A (es) Compuestos de n-formil-hidroxilamina
GT200600430A (es) Compuestos de carboxiamina y metodos de uso de los mismos
ECSP11010930A (es) Nuevos compuestos químicos
GT200600428A (es) Compuestos organicos
CO6511283A2 (es) Primidinas sustituidas útiles en el tratamiento de enfermedades tales como cancer
GT200500103A (es) 4-fenilamino-quinazolin-6-il-amidas
CO6511220A2 (es) Quinazolinas como inhibidores de los canales iónicos de potasio
CR20140422A (es) Composiciones de enzima digestiva estable
NI200900148A (es) COMPUESTOS TRICÍCLICOS, COMPOSICIONES, Y PROCEDIMIENTOS. Caso: PC33536A
GT200600205A (es) Nuevos herbicidas
GT200500242A (es) Procesos para la preparaciòn de 2-(2,6-dioxopiperidin-3-il)-1-oxoisoindolinas sustituidas
GT200800218A (es) Compuestos organicos
BR112012033350A2 (pt) "composição e métodos para modular a via de sinalização de wnt"
GT200600217A (es) Proceso para la sintesis de compuestos organicos
GT200800103A (es) 5-aril isoxazolinas para controlar plagas de invertebrados
ECSP11010778A (es) Amidofenoxiindazoles útiles como inhibidores de c-met
GT200700058A (es) Nuevos derivados de piridazina
ECSP078060A (es) 2,4-diamino-pirimidinas como inhibidores de aurora
GT200600208A (es) Compuestos organicos